A 62-year-old woman with COPD (FEV₁ 45% predicted) and emphysema-predominant disease presents with progressive dyspnea and limited exercise tolerance. She is currently on inhaled corticosteroids and formoterol. Which drug is the first-line add-on to improve bronchodilation and exercise capacity?

Explanation

## First-Line Add-On Bronchodilator in Moderate-to-Severe COPD **Key Point:** Tiotropium (long-acting muscarinic antagonist/LAMA) is the first-line add-on bronchodilator in patients already on ICS + LABA. It provides additional bronchodilation and improves exercise capacity and symptoms [cite:GOLD 2023; Harrison 21e Ch 297]. ### COPD Pharmacotherapy Ladder | COPD Severity | First-Line | Add-On Bronchodilator | Add-On Anti-Inflammatory | |---|---|---|---| | Mild (FEV₁ ≥ 80%) | SABA or SAMA | — | — | | Moderate (FEV₁ 50–79%) | LABA or LAMA | LABA + LAMA | — | | Severe (FEV₁ 30–49%) | ICS + LABA | Add LAMA | Roflumilast (if exacerbations) | | Very Severe (FEV₁ < 30%) | ICS + LABA + LAMA | — | Roflumilast ± LVRS | ### Why Tiotropium in This Patient? - Already on ICS + LABA (formoterol) ✓ - FEV₁ 45% (moderate-to-severe) ✓ - Needs additional bronchodilation (different class) ✓ - Emphysema phenotype benefits from LAMA ✓ ### Mechanism & Benefits - Long-acting anticholinergic → sustained bronchodilation - Reduces intrinsic tone in small airways (key in emphysema) - Improves exercise capacity and dyspnea - Once-daily dosing (improves adherence) - Well-tolerated; no systemic absorption **High-Yield:** LABA + LAMA combination (dual bronchodilation) is superior to LABA + ICS alone for exercise capacity and exacerbation prevention in moderate-to-severe COPD [cite:GOLD 2023]. **Clinical Pearl:** Tiotropium is available as monotherapy (Spiriva) or in fixed-dose combinations with LABA (Stiolto, Anoro). The patient is on formoterol (LABA) separately, so adding tiotropium achieves dual bronchodilation.